Cite

    Hofmann, D. et al. (2021). Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet infectious diseases. 21 (8), pp. 1151-1160. [Online].